aTyr Pharma, Inc. Stock

$5.23

6.77% yesterday

Nasdaq, Aug 12, 10:15 pm CET

ISIN

US0021201035

Symbol

ATYR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

aTyr Pharma, Inc. Stock price

$5.23

+1.59 43.68% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

-0.38 6.77%

ISIN

US0021201035

Symbol

ATYR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$549.7m

Enterprise Value

$474.7m

Net debt

positive

Cash

$76.4m

Shares outstanding

89.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 359.3

EV/Sales

- | 310.2

EV/FCF

negative

P/B

7.3

Financial Health

Equity Ratio

72.3%

Return on Equity

-91.4%

ROCE

-77.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $1.5m

EBITDA

$-65.3m | $-75.5m

EBIT

$-67.1m | $-68.3m

Net Income

$-63.4m | $-60.4m

Free Cash Flow

$-62.2m

Growth (TTM | estimate)

Revenue

-100.0% | 537.5%

EBITDA

-12.4% | -13.7%

EBIT

-14.1% | -0.6%

Net Income

-17.6% | 5.7%

Free Cash Flow

-7.3%

EPS

$-0.7

FCF per Share

$-0.7

Short interest

27.9%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

aTyr Pharma, Inc. Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a aTyr Pharma, Inc. forecast:

16x Buy

94%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a aTyr Pharma, Inc. forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from aTyr Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	14 14	9% 9% -
- Research and Development Expense	53 53	14% 14% -
EBITDA	-65 -65	12% 12% -
- Depreciation and Amortization	1.75 1.75	154% 154% -
EBIT (Operating Income) EBIT	-67 -67	14% 14% -
Net Profit	-63 -63	18% 18% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

aTyr Pharma, Inc. Stock News

Neutral

GlobeNewsWire

●

5 days ago

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2025 results and provided a corporate update. “With the recent completion of the last patient visit in our...

Neutral

GlobeNewsWire

●

22 days ago

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last patient has completed their last visit in the Company's Phase 3 EFZO-FIT™ study of its lead therapeutic can...

Neutral

GlobeNewsWire

●

about 2 months ago

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000 ® Index and broad market Russell 3000® Index, effective afte...

More aTyr Pharma, Inc. News

Company Profile

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Head office	United States
CEO	Sanjay Shukla
Founded	2005
Website	www.atyrpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now